Impact of Exercise on Myasthenia Gravis: Insights from a Patient-Reported Survey on Activity Patterns and Effects

• by Stefanie Glaubitz, Stefanie Meyer, Johanna Loris, Rachel Zeng, Karsten Kummer, Tania Garfias-Veitl, Ariana Seraji, Lina Hassoun, Denise Rohleder, Ina Hunger, Jana Zschüntzsch

• December 17, 2025

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

• by Kathryn Wighton

• May 11, 2026

• 2 min

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

• by Andrea Surnit

• June 18, 2026

• 4 min

Burden of and risk factors for neurological complications in critical illness

• by Victoria A. McCredie, Thomas P. Bleck, Sherry Hsiang-Yi Chou, E. Wesley Ely, Margaret S. Herridge, Julie Kromm, Pedro Kurtz, Nicola Latronico, Mypinder S. Sekhon, Gentle Sunder Shrestha, Romain Sonneville, Robert D. Stevens, Shawniqua Williams Roberson, Tarek Sharshar

• June 30, 2026